Muallem MZ, Braicu I, Nassir M, Richter R, Sehouli J, Arsenic R. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
Anticancer Res 2014;
34:393-399. [PMID:
24403493]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM
The purpose of the present study was to investigate the possible association between Excision repair cross-complementing group 1 (ERCC1) score and platinum resistance in first-line chemotherapy for ovarian cancer.
PATIENTS AND METHODS
ERCC1 Expression was determined using immunohisto-chemistry in 68 patients with platinum-responding tumor and 30 with platinum-resistant tumors. The primary end-point of this study was the association between the expression of ERCC1 protein with resistance to standard platinum-based chemotherapy in primary ovarian cancer.
RESULTS
In pairwise comparisons, the overall survival (OS) for patients with ovarian cancer, who were non-responders to platinum-based chemotherapy with low or intermediate H-score for ERCC1 was better than that of non-responders with high H-score for ERCC1 [median OS=21 (16.8-25.2 months) and 28 (14.6-41.4 months) vs. 15 months (6.2-23.8 months), p-value=0.048, and p-value=0.017, respectively].
CONCLUSION
There were no significant differences in the progression-free survival between those with low, intermediate and high H-score for ERCC1. There is no statistically significant relationship between ERCC1 score and response to platinum-based chemotherapy in patients with primary ovarian cancer.
Collapse